MGTA News and Press, Magenta Therapeutics Inc. From 03/15/19

Gainers:  Soleno Therapeutics (NASDAQ: SLNO ) +210% . Achieve Life Sciences (NASDAQ: ACHV ) +33% . Catasys (NASDAQ: CATS ) +26% . Prana Biotechnology (NASDAQ: PRAN ) +24% . Avid Technology (NASDAQ: AVID ) +23% . Magenta Therapeutics (NASDAQ: MGTA ) +22% . Leap Therapeutics (NASD...

Agilent (NYSE: A ) initiated with Buy rating and $92 (14% upside) price target at UBS. More news on: Agilent Technologies, Inc., Amgen Inc., Fluidigm Corporation, Healthcare stocks news, Stocks on the move, , Read more ...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled to present at the following investor conferences: Cowen Healthcar...

-- Additional follow-up on patients with cerebral adrenoleukodystrophy (cALD) treated with MGTA-456 in Phase 2 study in inherited metabolic disorders (IMDs) shows persistent resolution of brain inflammation on MRI and stable Loes disease scores -- -- Additional follow-up on patients wi...

-- Data in non-human primates from C100 program show potent stem and immune cell depletion with anti-CD45 amanitin ADC that is well tolerated at efficacious doses -- -- C200 development candidate, anti-CD117 amanitin ADC, showed potent and selective stem cell depletion and immune syste...

-- A single dose of MGTA-145 plus plerixafor mobilized two to three times more stem cells in non-human primates than multi-day regimen of current standard of care G-CSF -- -- Cells mobilized with MGTA-145 plus plerixafor rapidly engrafted in non-human primates following autologous tran...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company is scheduled to present at the Guggenheim Healthcare Talks Idea Forum Oncology Day...